China Meheco intends to form a Chinese pharmaceutical joint venture (JV) through its subsidiary with a capital of CNY10m ($1.51m).

To be based in Hubei, a 51% share in the JV will be owned by China Meheco with an investment of CNY5.1m ($0.77m).

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Recordati has purchased Bayer Consumer Care health brands Transipeg, TransipegLib and Colopeg.

“LP Pharmaceutical (Xiamen) has secured $30m in a series B venture financing round.”

Transipeg and TransipegLib are macrogol-based laxatives used to treat constipation symptoms in adults, while Colopeg is a large-volume bowel cleanser used while preparaing for endoscopic exploration.

Novartis has signed an agreement to acquire Ultragenyx Pharmaceutical’s rare pediatric disease priority review voucher (PRV) for $130m.

The PRV was granted in November, following the approval of MEPSEVII (vestronidase alfa) by the US Food and Drug Administration (FDA).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The drug is indicated for the treatment of Mucopolysaccharidosis VII in children and adults.

Novartis is a Switzerland-based pharmaceutical company, while Ultragenyx is a biopharmaceutical company based in the US.

LP Pharmaceutical (Xiamen) has secured $30m in a series B venture financing round led by SDIC Fund Management Corporation.

The financing round also included participation from CMB International Capital Corporation and Zhangzhou Pien Tze Huang Pharmaceutical.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Imagene’s Oncology Intelligence (OI) Suite has won the Innovation Award for Precision Oncology, for transforming how pharma designs and runs oncology trials. From AI-driven biomarker discovery to smarter patient stratification, see how Imagene is cutting time, cost and risk in cancer drug development.

Discover the Impact